Indication |
As an ophthalmic for the temporary relief of the signs and
symptoms of seasonal allergic conjunctivitis. Also used as a nasal spray
for allergic rhinitis. |
Pharmacodynamics |
Levocabastine is a selective histamine H1-receptor antagonist
exerting inhibitory effects on the release of chemical mediators from
mast cells and on the chemotaxis of polymorphonuclear leukocytes and
eosinophils. Both histamine and antigens induced conjunctivitis can be
inhibited by levocabastine. Levocabastine can also reduce symptoms of
allergic rhinitis by preventing an increase in vascular permeability of
nasal mucosa. |
Mechanism of action |
Levocabastine is a potent, selective histamine H1-receptor
antagonist. It works by competing with histamine for H1-receptor sites
on effector cells. It thereby prevents, but does not reverse, responses
mediated by histamine alone. Levocabastine does not block histamine
release but, rather, prevents histamine binding and activity.
Levocabastine also binds neurotensin 2 receptors and serves as a
neurotensin agonist. This can induce some degree of analgesia. |
Absorption |
After instillation in the eye, levocabastine is systemically absorbed, albeit at low levels. |
Volume of distribution |
Not Available |
Protein binding |
Not Available |
Metabolism |
Mostly unchanged. 10 to 20% is metabolized to the acylglucuronide of levocabastine. |
Route of elimination |
Not Available |
Half life |
36 hours (after oral administration) |
Clearance |
Not Available |
Toxicity |
Adverse effects include visual disturbances, dry mouth, cough, nausea, eyelid edema and lacrimation. |
Comments
Post a Comment